TABLE 5.
Fold enrichment | P value | |
---|---|---|
fWBI, dorsolateral prefrontal cortex | ||
aMHC class II receptor activity | >100.00 | 1.50E–04 |
Platelet-derived growth factor binding | >100.00 | 1.50E–04 |
aMHC class II protein complex binding | >100.00 | 2.66E–04 |
aPeptide antigen binding | >100.00 | 5.29E–05 |
Integrin binding | 34.91 | 3.63E–02 |
fWBI, hippocampus | ||
aMHC class II receptor activity | >100.00 | 1.26E–05 |
aPeptide antigen binding | >100.00 | 1.03E–06 |
aMHC class II protein complex binding | >100.00 | 1.11E–02 |
fWBI, white matter | ||
bOpsonin receptor activity | 89.16 | 1.20E–03 |
Tumor necrosis factor binding | 79.25 | 2.78E–02 |
ICAM-3 receptor activity | 79.25 | 2.75E–02 |
Glutamate-gated calcium ion channel activity | 71.33 | 1.76E–03 |
NMDA glutamate receptor activity | 67.93 | 1.42E–04 |
Calcium-dependent protein kinase C activity | 59.44 | 3.81E–02 |
bComplement component C3b binding | 59.44 | 3.78E–02 |
Benzodiazepine receptor activity | 59.44 | 2.39E–03 |
Lipoteichoic acid binding | 59.44 | 3.75E–02 |
CCR2 chemokine receptor binding | 59.44 | 3.72E–02 |
TBI, white matter | ||
aMHC class II receptor activity | >100.00 | 2.78E–02 |
Platelet-derived growth factor receptor binding | >100.00 | 4.06E–02 |
CXCR chemokine receptor binding | >100.00 | 4.13E–02 |
Chemokine activity | 53.68 | 1.06E–02 |
Cytokine binding | 34.38 | 5.49E–03 |
Cytokine receptor activity | 28.28 | 3.99E–02 |
bSerine-type endopeptidase activity | 16.99 | 7.86E–03 |
aPeptide binding | 13.13 | 4.87E–02 |
Notes. Analyses completed in Gene Ontology enrichment analysis tool. Maximum fold-enrichment values are truncated at 100. The top 10 enriched ontologies are reported in order of decreasing fold-enrichment and statistical significance, multiplicity adjusted P values ≤ 0.05 were considered significant. Overarching molecular function:
MHC class II peptide antigen presentation
complement activation.